Resonant (RESN) 10-Q 9 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 08, 2017
Document and Entity Information
Entity Registrant Name	Resonant Inc
Entity Central Index Key	1,579,910
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		16,782,254

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 13,530,000	$ 5,084,000
Accounts receivable	65,000	56,000
Prepaid expenses and other current assets	308,000	160,000
Investments held-to-maturity	0	4,747,000
TOTAL CURRENT ASSETS	13,903,000	10,047,000
PROPERTY AND EQUIPMENT
Property and equipment	2,603,000	2,269,000
Less: Accumulated depreciation and amortization	(1,737,000)	(1,275,000)
PROPERTY AND EQUIPMENT, NET	866,000	994,000
NONCURRENT ASSETS
Intangible assets, net	1,325,000	1,253,000
Restricted cash	100,000	100,000
Goodwill	825,000	789,000
Deferred tax asset	24,000	0
Other assets	19,000	16,000
TOTAL OTHER NONCURRENT ASSETS	2,293,000	2,158,000
TOTAL ASSETS	17,062,000	13,199,000
CURRENT LIABILITIES
Accounts payable	809,000	905,000
Accrued expenses	122,000	35,000
Accrued salaries and payroll related expenses	1,069,000	1,765,000
Deferred revenue, current	261,000	279,000
Deferred rent, current	0	20,000
TOTAL CURRENT LIABILITIES	2,261,000	3,004,000
LONG-TERM LIABILITIES
Deferred revenue	0	46,000
Deferred rent	8,000	0
Deferred income taxes	0	16,000
TOTAL LIABILITIES	2,269,000	3,066,000
Commitments and contingencies (Note 8)	0	0
STOCKHOLDERS’ EQUITY
Common stock, $0.001 par value, 47,000,000 authorized and 12,468,647 outstanding as of December 31, 2016, and 16,479,806 outstanding as of September 30, 2017	16,000	12,000
Preferred stock, $0.001 par value, 3,000,000 authorized and none outstanding as of December 31, 2016 and September 30, 2017	0	0
Additional paid-in capital	74,282,000	56,331,000
Accumulated other comprehensive loss	(5,000)	(51,000)
Accumulated deficit	(59,500,000)	(46,159,000)
TOTAL STOCKHOLDERS’ EQUITY	14,793,000	10,133,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 17,062,000	$ 13,199,000

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	47,000,000	47,000,000
Common stock, shares outstanding	16,479,806	12,468,647
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
REVENUES	$ 106,000	$ 25,000	$ 482,000	$ 115,000
OPERATING EXPENSES
Research and development	2,336,000	1,599,000	6,956,000	4,299,000
General and administrative	1,978,000	2,407,000	6,939,000	5,866,000
TOTAL OPERATING EXPENSES	4,314,000	4,006,000	13,895,000	10,165,000
NET OPERATING LOSS	(4,208,000)	(3,981,000)	(13,413,000)	(10,050,000)
OTHER INCOME, NET
Interest and investment income	14,000	4,000	39,000	10,000
Other expense	(6,000)	0	(7,000)	0
TOTAL OTHER INCOME, NET	8,000	4,000	32,000	10,000
LOSS BEFORE INCOME TAXES	(4,200,000)	(3,977,000)	(13,381,000)	(10,040,000)
Provision for (benefit from) income taxes	16,000	0	40,000	(1,000)
NET LOSS	(4,184,000)	(3,977,000)	(13,341,000)	(10,041,000)
Foreign currency translation adjustment, net of tax	(17,000)	(1,000)	46,000	(1,000)
COMPREHENSIVE LOSS	$ (4,201,000)	$ (3,978,000)	$ (13,295,000)	$ (10,042,000)
NET LOSS PER SHARE - BASIC AND DILUTED (in dollars per share)	$ (0.28)	$ (0.39)	$ (0.94)	$ (1.14)
Weighted average shares outstanding-basic and diluted (in shares)	14,757,688	10,095,395	14,233,774	8,772,582

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Stockholders' Equity - 9 months ended Sep. 30, 2017 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Balance (in shares) at Dec. 31, 2016	12,468,647	12,468,647
Beginning Balance at Dec. 31, 2016	$ 10,133	$ 12	$ 56,331	$ (46,159)	$ (51)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock for compensation (in shares)		532,031
Stock-based compensation	2,876		2,876
Sales of common stock, net of offering costs (in shares)		3,372,479
Sales of common stock, net of offering costs	15,025	$ 4	15,021
Exercise of warrants, cashless (in shares)		78,831
Exercise of stock options (in shares)		27,818
Exercise of stock options	54		54
Net loss	(13,341)			(13,341)
Foreign currency translation adjustments, net of tax	$ 46				46
Balance (in shares) at Sep. 30, 2017	16,479,806	16,479,806
Ending Balance at Sep. 30, 2017	$ 14,793	$ 16	$ 74,282	$ (59,500)	$ (5)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (13,341)	$ (10,041)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	554	502
Deferred tax benefit	(40)	0
Stock-based compensation	2,024	1,350
Non-cash investment income	0	(2)
Non-cash patent write-off	0	14
Changes in assets and liabilities:
Accounts receivable	(9)	(16)
Prepaids and other current assets	(112)	(18)
Other assets	(3)	0
Accounts payable	113	274
Accrued expenses	86	123
Accrued salaries and payroll related expenses	159	49
Deferred revenue	(67)	208
Deferred rent	(12)	(26)
Net cash used in operating activities	(10,648)	(7,583)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(494)	(375)
Expenditures for patents and domain names	(244)	(176)
Payment for acquisition of business assets, net of acquired cash		(452)
Redemption of investments held-to-maturity	4,747	5,255
Purchase of investments held-to-maturity	0	(12,249)
Net cash provided by (used in) investing activities	4,009	(7,997)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from the sale of common stock from private placement offering	15,025	5,177
Net proceeds from the sale of common stock from underwritten public offering	0	10,621
Proceeds from the exercise of stock options	54	0
Net cash provided by financing activities	15,079	15,798
Effects of currency translation on cash	6	0
NET INCREASE IN CASH AND CASH EQUIVALENTS	8,446	218
CASH AND CASH EQUIVALENTS — Beginning of period	5,084	2,501
CASH AND CASH EQUIVALENTS — End of period	13,530	2,719
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Taxes Paid	1	1
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES
Issuance of common stock in settlement of liability	272	110
Issuance of common stock in acquisition of business assets	0	545
Accrued consideration for acquisition of business assets	0	61
Stock options issued in settlement of liability	580	0
Property and equipment included in accounts payable	30	0
Patents included in accounts payable	$ 33	$ 0

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	ORGANIZATION AND DESCRIPTION OF BUSINESS Overview Resonant Inc. is a late-stage development company located in Goleta, California. We were incorporated in Delaware in January 2012 as a wholly owned subsidiary of Superconductor Technologies Inc., or STI, but had not conducted any operations through June 16, 2013. Resonant LLC, a limited liability company, was formed in California in May 2012. We commenced business on July 6, 2012 with initial contributions from our founders and STI. We changed our form of ownership from a limited liability company to a corporation in an exchange transaction in June 2013. We are the successor of Resonant LLC. We completed our initial public offering, or IPO, on May 29, 2014. We acquired all of the issued and outstanding capital stock of GVR Trade S.A, or GVR, on July 6, 2016. GVR is a wholly owned subsidiary of Resonant Inc. We are creating an innovative software, intellectual property, or IP, and services platform that we believe has the ability to increase designer efficiency, reduce the time to market and lower unit costs in the design of filters for radio frequency, or RF, front-ends for the mobile device industry. The RF front-end, or RFFE, is the circuitry in a mobile device responsible for analog signal processing and is located between the device’s antenna and its digital baseband. The platform we are developing is based on fundamentally new technology that we call Infinite Synthesized Networks®, or ISN®, to configure and connect resonators, the building blocks of RF filters. Filters are a critical component of the RF front-end used to select desired radio frequency signals and reject unwanted signals. Our ISN® platform allows us to develop unique, custom designs that address the increasing complexity of the RFFE due to carrier aggregation, or CA, by both reducing the size of the filter and improving performance. Our goal is to utilize our ISN® platform to support our customers in reducing their time to develop complex filter designs, to access new classes of filter designs, and to do it more cost effectively. We are validating and commercializing our technology through the creation of filter designs that address the problems in the high growth RFFE industry created by the growing number of frequency bands in mobile devices. We are developing a series of single-band surface acoustic wave, or SAW, filter designs for frequency bands presently dominated by larger and more expensive bulk acoustic wave, or BAW, filters. We are also developing multiplexer filter designs for two or more bands to address the CA requirements of our customers. Finally, we are developing unique filter designs, enabled by ISN®, to replace multiple filters and associated componentry for many bands, with higher performance. Our design development agreements with our customers generally include up-front payments to assist in covering a portion of the development costs of the designs, as well as additional milestone payments upon completion of the design. We believe licensing our solutions is the most direct and effective means of delivering our solutions to the market. Our target customers make part or all of the RF front-end. We intend to retain ownership of our solutions, and we expect to be compensated through license fees and royalties based on sales of RF front-end filters that incorporate our solutions. We currently do not intend to manufacture or sell any physical products. In addition, we are exploring the possibility of licensing portions of our ISN ® suite to designers and manufacturers of RF products in the mobile industry. Capital Resources and Liquidity We are using the net proceeds from the sales of our common stock for product development to commercialize our technology, research and development, the development of our patent strategy and expansion of our patent portfolio, as well as for working capital and other general corporate purposes. Our costs include employee salaries and benefits, compensation paid to consultants, capital costs for research and other equipment, costs associated with development activities including travel and administration, legal expenses, sales and marketing costs, general and administrative expenses, and other costs associated with a late-stage development, publicly-traded technology company. However, this is highly dependent on the nature of our development efforts and our success in commercialization. We continue to add employees for research and development, as well as general and administrative functions, to support our efforts. Additionally, we continue to incur consulting expenses related to technology development and other efforts as well as legal and related expenses to protect our intellectual property. The amounts that we actually spend for any specific purpose may vary significantly and will depend on a number of factors including, but not limited to, our expected cash resources, the pace of progress of our commercialization and development efforts, actual needs with respect to product testing, research and development, market conditions, and changes in or revisions to our marketing strategies. In addition, we may invest in complementary products, technologies or businesses. We have earned minimal revenues since inception, and our operations have been funded with initial capital contributions and proceeds from the sale of equity securities and debt. At December 31, 2016 and September 30, 2017 , we had incurred accumulated losses of $46.2 million and $59.5 million , respectively. The losses are primarily the result of research and development costs associated with commercializing our technology, combined with start-up, financing and public company costs. We expect to continue to incur substantial costs for commercialization of our technology on a continuous basis because our business model involves developing and licensing custom filter designs. Our condensed consolidated financial statements account for the continuation of our business as a going concern. We are subject to the risks and uncertainties associated with a new business. Our principal source of liquidity as of September 30, 2017 consists of existing cash and cash equivalents of $13.5 million , which includes $7.5 million of net proceeds we raised in September 2017 in a private placement of common stock and warrants. In the first nine months of 2017, we used approximately $11.3 million in cash and investments. Due to these conditions, substantial doubt exists as to our ability to continue as a going concern. After evaluation of these conditions, we believe our current resources will provide sufficient funding for planned operations into the second half of 2018. If necessary, we will seek to raise additional capital from the sale of equity securities or the incurrence of indebtedness to allow us to continue operations. There can be no assurance that additional financing will be available to us on acceptable terms, or at all. Additionally, if we issue additional equity securities to raise funds, whether to existing investors or others, the ownership percentage of our existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of common stock. Additionally, we may be limited as to the amount of funds we can raise pursuant to SEC rules and the continued listing requirements of NASDAQ. If we cannot raise needed funds, we might be forced to make substantial reductions in our operating expenses, which could adversely affect our ability to implement our business plan and ultimately our viability as a company. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty. We have a Form S-3 universal shelf registration statement on file with the SEC. The universal shelf registration statement on Form S-3 permits us to sell, in one or more public offerings, shares of our common stock, shares of preferred stock or debt securities, or any combination of such securities and warrants to purchase securities, for proceeds in an aggregate amount of up to $35.0 million , subject to limitations on the amount of securities we may sell in any twelve month period. As of September 30, 2017 , we have raised a total of $11.5 million of gross proceeds from the sale of 2,715,000 shares of our common stock, leaving approximately $23.5 million of securities available for issuance pursuant to the Form S-3. The Form S-3 will expire in May 2019. The accompanying condensed consolidated financial statements at September 30, 2017 and for the three and nine months ended September 30, 2016 and 2017 are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Prior period figures have been reclassified, wherever necessary, to conform to current presentation. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2016 have been derived from our audited consolidated financial statements as of that date. The condensed consolidated financial statements included herein have been prepared by us pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted pursuant to such rules and regulations. The financial statements should be read in conjunction with our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2016 . Our operating results will fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Use of Estimates —The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. In the opinion of management, all adjustments (consisting of normal accruals) considered for a fair presentation have been included. Significant estimates made in preparing these financial statements include (a) assumptions to calculate the fair values of financial instruments, warrants and equity instruments and other liabilities and the deferred tax asset valuation allowance and (b) the useful lives for depreciable and amortizable assets. Actual results could differ from those estimates. In the opinion of management, all adjustments, including normal recurring accruals considered necessary for a fair presentation, have been included. Consolidation —The accompanying financial statements include the accounts of the Company and its wholly-owned subsidiary, GVR Trade, S.A. All significant intercompany balances and transactions have been eliminated. Cash and Cash Equivalents —We consider all liquid instruments purchased with a maturity of three months or less to be cash equivalents. Concentration of Credit Risk —We maintain checking accounts at one U.S. financial institution. The U.S. bank accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account owner. GVR Trade S.A., our wholly owned Swiss-based subsidiary maintains checking accounts at one major national financial institution. Management believes we are not exposed to significant credit risk due to the financial position of the depository institutions in which our deposits are held. Restricted Cash —Restricted cash at December 31, 2016 and September 30, 2017 represents cash held within a certificate of deposit with a financial institution, which serves as collateral for our corporate credit cards. The restriction on the cash will lapse in conjunction with the expiration of the use of the corporate credit cards. Investments —Securities held-to-maturity: Management determines the appropriate classification of investments at the time of purchase and reevaluates such designation as of each balance sheet date. Investment securities are classified as held-to-maturity when we have the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization is included in investment income. Interest on securities classified as held-to-maturity is included in investment income. When the fair value of an investment instrument classified as held-to-maturity is less than its amortized cost, management assesses whether or not: (i) we have the intent to sell the instrument or (ii) it is more likely than not that we will be required to sell the instrument before its anticipated recovery. If either of these conditions is met, we must recognize an other-than-temporary impairment for the difference between the instrument’s amortized cost basis and its fair value, and include such amounts in net securities gains (losses). For investment instruments that do not meet the above criteria and are not expected to be recovered at the amortized cost basis, the instrument is considered other-than-temporarily impaired. For these instruments, we separate the total impairment into the credit loss component and the amount of the loss related to other factors. In order to determine the amount of the credit loss, we calculate the recovery value by performing a discounted cash flow analysis based on the current cash flows and future cash flows management expects to recover. The discount rate is the effective interest rate implicit in the underlying instrument. The amount of the total other-than-temporary impairment related to credit loss is recognized in earnings and is included in net securities gains (losses). The amount of the total other-than-temporary impairment related to other factors is recognized in other comprehensive income. For investment instruments that have other-than-temporary impairment recognized through earnings, if through subsequent evaluation there is a significant increase in the cash flow expected, the difference between the amortized cost basis and the cash flows expected to be collected is accreted as interest income. During 2017 , we invested in commercial papers and certificates of deposit that were classified as investments held-to-maturity. Additionally, we maintained money market fund balances that were classified as cash and cash equivalents. As of September 30, 2017 , all of our investments held-to-maturity have matured and we have no investments classified as held-to-maturity. We recorded interest and investment income of $4,000 and $14,000 for the three months ended September 30, 2016 and 2017 , respectively, and $10,000 and $39,000 for the nine months ended September 30, 2016 and 2017, respectively, associated with our cash and investment accounts. Fair Value of Financial Instruments —We measure certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The carrying amounts of our financial instruments, including cash equivalents, restricted cash, investments held-to-maturity, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Accounts Receivable —Trade accounts receivable are stated net of allowances for doubtful accounts. Management estimates the allowance for doubtful accounts based on review and analysis of specific customer balances that may not be collectible, customer payment history and any other customer-specific information that may impact ability to collect the receivable. Accounts are considered for write-off when they become past due and when it is determined that the probability of collection is remote. There was no allowance for doubtful accounts at December 31, 2016 and September 30, 2017 . Property and Equipment —Property and equipment consists of leasehold improvements associated with our offices, software purchased during the normal course of business, equipment and office furniture and fixtures, all of which are recorded at cost. In July 2016, other property and equipment were acquired as part of the purchase of GVR and were initially recorded at their fair value. Depreciation and amortization is recorded using the straight-line method over the respective useful lives of the assets ranging from three to five years. Leasehold improvements are amortized over the shorter of lease term or useful life. Long-lived assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. Intangible Assets, net —Intangible assets are recorded at cost and amortized over the useful life. In the case of business combinations, intangible assets are recorded at fair value. At December 31, 2016 and September 30, 2017 , intangible assets, net, includes patents and a domain name and other intangible assets purchased as part of our acquisition of GVR, including customer relationships, technology and a trademark. Intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. Goodwill— At September 30, 2017 , goodwill represents the difference between the price paid to acquire GVR and the fair value of the assets acquired, net of assumed liabilities. We review goodwill for impairment annually and whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. Revenue Recognition —Revenue consists primarily of fees received in connection with filter design projects with customers. Contracts may involve upfront non-refundable fees, intended to support our initial engineering product development efforts, as well as milestone payments based upon the successful completion of certain deliverables. In relation to the upfront non-refundable fees, we recognize revenue in accordance with the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 605, Revenue Recognition. We recognize revenue as the services are performed over the initial engineering filter design development period and when all of the following criteria have been met: persuasive evidence of an arrangement exists, services have been rendered, collection of the revenue is reasonably assured, and the fees are fixed or determinable. We record the expenses related to these projects in the periods incurred and they are generally included in research and development expense. In addition to upfront non-refundable payments, the filter design projects may include certain milestone payments upon successful filter design or a design stage completion. These filter design projects are associated with complex technology development, and as such we do not have certainty about our ability to achieve the program milestones. Achievement of the milestone is generally dependent on the filter design specifications and the milestone typically needs to be accepted by the customer. The payment associated with achieving the milestone is generally commensurate with our effort or the value of the deliverable and is generally non-refundable. We record revenue associated with the milestone payments in accordance with ASC Topic 605-28 Milestone Method whereby we record revenue upon successful completion of the related milestone and when collection of the revenue is reasonably assured. During the three and nine months ended September 30, 2017 , we recorded revenue of $106,000 and $482,000 , respectively, primarily related to the development of filter designs. As of September 30, 2017 , we have recorded $261,000 in deferred revenue, primarily related to our filter design development projects. Research and Development —Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with ASC Topic 730-10, Research and Development . Operating Leases —We lease office space and research facilities under operating leases. Certain lease agreements contain free or escalating rent payment provisions. We recognize rent expense under such leases on a straight-line basis over the term of the lease. Lease renewal periods are considered on a lease-by-lease basis in determining the lease term. Stock-Based Compensation —We account for employee stock options in accordance with ASC Topic 718, Compensation-Stock Compensation . For stock options issued to employees and directors we use the Black-Scholes option valuation model for estimating fair value at the date of grant. For stock options issued for services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC Topic 505-50 , Equity , or ASC 505-50, as amended. Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these options, as calculated using the Black-Scholes option valuation model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options or warrants are fully vested. We account for restricted stock units issued to employees at fair value, based on the market price of our stock on the date of grant, net of estimated forfeitures. Compensation expense is recognized for the portion of the award that is ultimately expected to vest over the period during which the recipient renders the required services to the Company generally using the straight-line single option method. The fair value of non-employee restricted stock units awarded are remeasured as the awards vest, and the resulting increase or decrease in fair value, if any, is recognized as an increase or decrease to compensation expense in the period the related services are rendered. In the case of award modifications, we account for the modification by recognizing the effect of the modification in the period the award was modified. Stock-based compensation expense is included in research and development expenses and general and administrative expenses. Earnings Per Share, or EPS —EPS is computed in accordance with ASC Topic 260, Earnings per Share , and is calculated using the weighted average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents unless the effect is to reduce a loss or increase the income per share. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method), the exercise of warrants (using the if-converted method) and the vesting of restricted stock unit awards. The following table presents the number of shares excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods below: Nine Months Ended September 30, 2016 2017 Common stock warrants 3,017,159 6,202,147 Common stock options 753,114 908,560 Non-vested restricted stock unit awards 874,075 1,401,693 Total shares excluded from net loss per share attributable to common stockholders 4,644,348 8,512,400 Income Taxes —We account for income taxes in accordance with ASC Topic 740, Income Taxes , or ASC 740, which requires the recognition of deferred tax assets and liabilities for the future consequences of events that have been recognized in our condensed consolidated financial statements or tax returns. The measurement of the deferred items is based on enacted tax laws. In the event the future consequences of differences between financial reporting bases and the tax bases of our assets and liabilities result in a deferred tax asset, ASC 740 requires an evaluation of the probability of being able to realize the future benefits indicated by such asset. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion or the entire deferred tax asset will not be realized. As part of the process of preparing our consolidated financial statements, we are required to estimate our income tax expense in each of the jurisdictions in which we operate. We also assess temporary differences resulting from differing treatment of items for tax and accounting differences. We record a valuation allowance to reduce the deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. For the period when we were organized as a limited liability company, we were treated as a partnership for federal and state income tax purposes under the entity classification domestic default rules. As of December 31, 2016 and September 30, 2017 , no liability for unrecognized tax benefits was required to be reported. We recognize interest and penalties related to income tax matters in income taxes, and there were none for the three and nine months ended September 30, 2016 and September 30, 2017 , respectively. We have filed, or are in the process of filing, tax returns that are subject to audit by the respective tax authorities. Although the ultimate outcome would be unknown, we believe that any adjustments that may result from tax return audits are not likely to have a material, adverse effect on our condensed consolidated results of operations, financial position or cash flows. Reclassifications —Certain amounts in the condensed consolidated statement of operations for the three and nine months ended September 30, 2016 have been reclassified to conform to the current year presentation. Business Combinations— We record business combinations using the acquisition method of accounting and, accordingly, allocate the fair value of purchase consideration to the assets acquired and liabilities assumed based on their fair values at the acquisition date. The excess of the fair value of the purchase consideration over the fair value of the assets acquired and liabilities assumed is recorded as goodwill. The results of operations of the business acquired are included in our consolidated results of operations beginning on the date of acquisition. Foreign Currency Translation —The Swiss Franc has been determined to be the functional currency for the net assets of our Swiss-based subsidiary. We translate the assets and liabilities to U.S. dollars at each reporting period using exchange rates in effect at the balance sheet date and record the effects of the foreign currency translation in accumulated other comprehensive income (loss) in shareholders' equity. We translate the income and expenses to U.S. dollars at each reporting period using the average exchange rate in effect for the period and record the effects of the foreign currency translation as other comprehensive income (loss) in the consolidated statements of comprehensive loss. Gains and losses resulting from foreign currency transactions are included in net loss in the consolidated statements of comprehensive loss. Recent Accounting Pronouncements Revenue from Contracts with Customers— In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) . The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , which defers the effective date of ASU No. 2014-09 for all entities by one year to annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. This ASU shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. Early adoption is permitted but not before the annual periods beginning after December 15, 2016, including interim periods within that reporting period. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net) . This ASU provides further guidance surrounding the recognition of revenue as well as guidance involving principal versus agent considerations. The effective date of this ASU is the same as ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing . This amendment provides clarification surrounding the identification of performance obligations and offers licensing implementation guidance. The effective date of this ASU is the same as ASU 2014-09. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606), Narrow-Scope Improvements and Practical Expedients, which provides further guidance surrounding certain aspects of ASU 2014-09. The effective date of this ASU is the same as ASU 2014-09. The new standards will become effective for us on January 1, 2018 and we plan to adopt at that time. We have reviewed our contracts which we believe will be impacted by the adoption and we have decided to adopt the standard using the modified retrospective approach with a cumulative effect of the initial application recognized at the date of adoption. We do not believe the adoption of this guidance will have a significant impact on our consolidated balance sheet, statement of comprehensive loss or statement of cash flow due to the relatively small number of contracts and nature of our contracts, which are primarily related to design development projects where we believe the revenue will be recognized over time, which is consistent with the current method of revenue recognition. Leases— In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , a comprehensive new leases standard that amends various aspects of existing accounting guidance for leases. It will require recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The main difference between previous U.S. GAAP and the amended standard is the recognition of lease assets and lease liabilities by lessees on the balance sheet for those leases classified as operating leases under previous U.S. GAAP. The accounting applied by a lessor is largely unchanged from that applied under previous U.S. GAAP. As a result, we will have to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing our right to use the underlying asset for the lease term on the balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We are currently reviewing the two leases we have and are evaluating the effects of the new guidance on our consolidated financial statements. We expect to report additional assets and liabilities related to these leases as a result of the new guidance, however, we do not expect it to have a material impact on our consolidated financial statements. Intangibles-Goodwill and Other— In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which simplifies the accounting for goodwill impairments by eliminating step 2 from the goodwill impairment test. The amended guidance will become effective for us commencing in the first quarter of fiscal 2019. We are currently evaluating the impact of this new standard. Compensation-Stock Compensation— In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , which provides clarity over the accounting for a change to the terms or conditions of a share-based payment award. The amendments in the update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The amendments in this update should be applied prospectively to an award modification on or after the adoption date. We plan to early adopt this guidance if, and when, we experience a share-based award modification.

ACQUISITION OF GVR TRADE S.A.

ACQUISITION OF GVR TRADE S.A.	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
ACQUISITION OF GVR TRADE S.A.	ACQUISITION OF GVR TRADE S.A. On July 6, 2016, we acquired all of the issued and outstanding capital stock of GVR Trade S.A. The purchase price, consisting of $661,000 in cash and 125,000 shares of our common stock with a fair value of $545,000 , based on a per share price of $4.36 as of the date of acquisition, was approximately $1.2 million . At the time of acquisition, we incurred approximately $92,000 of acquisition related expenses. GVR is a wholly owned direct subsidiary of Resonant. As of the acquisition date we recorded goodwill of approximately $824,000 which represented the excess of the purchase price over the fair value of the assets acquired. The fair value for the assets acquired and liabilities assumed were based upon independent calculations and valuations. We review goodwill for impairment annually and whenever events or circumstances indicate that the carrying amount of the assets may not be recoverable. The acquisition was not material to our condensed consolidated financial statements and we have included the financial results of the acquired business in our condensed consolidated financial statements from the date of acquisition. Pro forma historical results of operations of this business acquisition during the three and nine months ended September 30, 2016 have not been presented as it is not material to our condensed consolidated statements of comprehensive loss.

WARRANTS

WARRANTS	9 Months Ended
	Sep. 30, 2017
Warrants and Rights Note Disclosure [Abstract]
WARRANTS	WARRANTS From time to time, we have issued warrants to purchase shares of common stock. These warrants have been issued in connection with the financing transactions and consulting services. Our warrants are subject to standard anti-dilution provisions applicable to shares of our common stock. Private Placement Warrants In February 2017, we issued warrants to purchase 1,626,898 shares of our common stock at an exercise price of $8.25 in connection with our private placement sale of 1,626,898 shares of common stock. The warrants are exercisable for a period commencing 6 months and ending 30 months after the closing of the financing. We refer to these warrants as Private Placement Warrants - February 2017. We estimated the fair value of the Private Placement Warrants at $2,084,000 using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $4.91 per share, time to maturity of 3 years, volatility of 60% , zero expected dividend rate and risk free rate of 1.50% . The allocation of the fair value of these warrants was included in additional paid-in capital on the consolidated balance sheet. In September 2017, we issued warrants to purchase 1,832,860 shares of our common stock at an exercise price of $4.85 in connection with our private placement sale of 1,745,581 shares of common stock. The warrants are exercisable for a period commencing 6 months and ending 36 months after the closing of the financing. We refer to these warrants as Private Placement Warrants - September 2017. We estimated the fair value of the Private Placement Warrants at $3.2 million using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $4.49 per share, time to maturity of 3 years , volatility of 60% , zero expected dividend rate and risk free rate of 1.59% . The allocation of the fair value of these warrants was included in additional paid-in capital on the consolidated balance sheet. A roll-forward of warrant share activity from January 1, 2016 to September 30, 2016 is shown in the following table: Issued and Outstanding Warrants as of January 1, 2016 Warrants Issued Warrants Exercised/ Expired Issued and Outstanding Warrants as of September 30, 2016 Bridge Warrants 249,999 — — 249,999 Consulting Warrants 117,778 — (19,778 ) (1) 98,000 Financing Warrants 78,186 — — 78,186 Underwriting Warrants 310,500 — — 310,500 IR Consulting Warrants 48,000 — — 48,000 Private Placement Warrants — 2,096,724 2,096,724 Underwriting Warrants- Public Offering 2016 135,750 135,750 804,463 2,232,474 (19,778 ) 3,017,159 (1) During the nine months ended September 30, 2016 there were 19,778 common stock warrants that were exercised through a cashless exercise which resulted in 19,693 shares being issued. A roll-forward of warrant share activity from January 1, 2017 to September 30, 2017 is shown in the following table: Issued and Outstanding Warrants as of January 1, 2017 Warrants Issued Warrants Exercised/ Expired Issued and Outstanding Warrants as of September 30, 2017 Bridge Warrants 249,999 — — 249,999 Consulting Warrants 98,000 — (41,889 ) (1) 56,111 Financing Warrants 78,186 — — 78,186 Underwriting Warrants 310,500 — — 310,500 IR Consulting Warrants 48,000 — (42,000 ) (2) 6,000 Private Placement Warrants - 2016 1,995,124 — (89,281 ) (3) 1,905,843 Underwriting Warrants - Public Offering 2016 135,750 — — 135,750 Private Placement Warrants - February 2017 — 1,626,898 — 1,626,898 Private Placement Warrants - September 2017 — 1,832,860 — 1,832,860 2,915,559 3,459,758 (173,170 ) 6,202,147 (1) During the nine months ended September 30, 2017 , there were 41,889 common stock warrants that were exercised through cashless exercises which resulted in 41,800 shares being issued. (2) During the nine months ended September 30, 2017, 42,000 warrants expired. (3) During the nine months ended September 30, 2017, there were 89,281 common stock warrants that were exercised through cashless exercises which resulted in 37,031 shares being issued.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Common Stock Pursuant to our amended and restated certificate of incorporation, we are authorized to issue 47,000,000 shares of common stock. Holders of our common stock are entitled to dividends as and when declared by the Board of Directors, subject to rights and holders of all classes of stock outstanding having priority rights to dividends. There have been no dividends declared to date. Each share of common stock is entitled to one vote. On February 22, 2017, we completed the private placement sale of 1,626,898 units at a price of $4.61 per unit to one of our investors. Each unit consists of one share of our common stock and one warrant to purchase one share of our common stock at an exercise price of $8.25 for a period commencing six months and ending 30 months after the closing of the financing. Gross proceeds were $7.5 million . We incurred $29,000 of legal expenses in connection with the financing. The shares were issued pursuant to a registration statement that was declared effective by the SEC in April 2017. On September 28, 2017, we completed the first of two closings related to the private placement sale of 1,976,919 units at a price of $4.70 per unit to institutional and individual investors. Each unit consists of one share of our common stock and one warrant to purchase one share of our common stock at an exercise price of $4.85 per share for a period commencing six months and ending three years from the date of the first closing of the offering. We also issued to the placement agent in the financing, warrants to purchase an aggregate of 98,846 shares of our common stock at an exercise price of $4.85 per share for a period commencing six months and ending three years from the date of the first closing of the offering. Gross proceeds in the first closing for 1,745,581 units were $8.2 million with net proceeds of $7.5 million after deducting placement agent fees and offering expenses. The second closing, completed on October 2, 2017, was for 231,338 units and gross proceeds of $1.1 million with net proceeds of $1.0 million after deducting placement agent fees and offering expenses. Placement agent warrants issued in the first and second closings were 87,279 and 11,567 , respectively. We have a Form S-3 universal shelf registration statement on file with the SEC. The universal shelf registration statement on Form S-3 permits us to sell, in one or more public offerings, shares of our common stock, shares of preferred stock or debt securities, or any combination of such securities and warrants to purchase securities, for proceeds in an aggregate amount of up to $35.0 million , subject to limitations on the amount of securities we may sell in any twelve month period. As of September 30, 2017, we have raised a total of $11.5 million of gross proceeds from the sale of 2,715,000 shares of our common stock, leaving approximately $23.5 million of securities available for the issuance pursuant to the Form S-3. The Form S-3 will expire in May 2019. Preferred Stock Pursuant to our amended and restated certificate of incorporation, we are authorized to issue 3,000,000 shares of preferred stock. The Board of Directors has the authority, without action by our stockholders, to designate and issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. To-date, no preferred shares have been issued.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION 2014 Omnibus Incentive Plan In January 2014, our board of directors approved the 2014 Omnibus Incentive Plan and amended and restated the plan in March 2014. Our stockholders approved the Amended and Restated 2014 Omnibus Incentive Plan, or the 2014 Plan, in March 2014. Our 2014 Plan initially permitted for the issuance of equity based instruments covering up to a total of 1,400,000 shares of common stock. In June 2016, our board of directors and stockholders approved an increase of 1,300,000 shares and in June 2017 approved an additional increase of 3,250,000 shares of common stock bringing the total shares allowed under the plan to 5,950,000 . Option Valuation We have computed the fair value of options granted to employees and non-employees using the Black-Scholes option valuation model. The compensation costs of non-employee arrangements are subject to re-measurement at each reporting period over the vesting terms as earned. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The expected term used for options issued to non-employees is the contractual life and the expected term used for options issued to employees is the estimated period of time that options granted are expected to be outstanding. We have estimated the expected life of our employee stock options using the “simplified” method, whereby, the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to our lack of sufficient historical data. For consultants we use an estimated expected life of the remaining term of the stock option grant, which is initially ten years. Since our stock has not been publicly traded for a sufficiently long period of time, we are utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within our industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Stock Options to Employees and Consultants During the three and nine months ended September 30, 2016 , we granted incentive and non-qualified stock options for the purchase of 55,000 and 291,500 shares, respectively, of our common stock to our employees and a consultant. The stock options have an exercise price range of $1.93 per share to $5.26 per share with a term of 10 years . The stock options vest quarterly over sixteen quarters. The options granted had an aggregate grant date fair value of $166,000 and $467,000 for the three and nine months ended September 30, 2016 , respectively, utilizing the Black-Scholes option valuation model. During the three and nine months ended September 30, 2017 , we granted incentive stock options for the purchase of 131,500 and 299,880 shares, respectively, of our common stock to our employees. The stock options have an exercise price range of $4.36 per share to $4.68 per share with a term of 10 years . Of the shares granted in 2017, 125,880 options vested upon grant, 91,500 vested nine days after grant and the remaining 82,500 stock options vest quarterly over sixteen quarters. The stock options granted had an aggregate grant date fair value of $356,000 and $802,000 for the three and nine months ended September 30, 2017 , respectively, utilizing the Black-Scholes option valuation model. We estimated the fair value of stock options awarded during the nine months ended September 30, 2016 and 2017 using the Black-Scholes option valuation model. The fair values of stock options granted for the periods were estimated using the following assumptions: Stock Option Grants Awarded During the Nine Months Ended September 30, 2016 Stock Option Grants Awarded During the Nine Months Ended September 30, 2017 Stock Price $1.93 to $5.26 $4.36 to $4.68 Dividend Yield 0.00% 0.00% Expected Volatility 60% 60% Risk-free interest rate 1.30% - 1.78% 1.95% - 2.14% Expected Life 7 years 7 years Stock-based compensation expense related to stock options for employees was $157,000 and $100,000 for the three months ended September 30, 2016 and 2017 , respectively and was $420,000 and $332,000 for the nine months ended September 30, 2016 and 2017, respectively. We are also required to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual forfeitures differ from our estimates. We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent that actual forfeitures differ from our estimates, the difference is recorded as a cumulative adjustment in the period the estimates were revised. For the period from January 1, 2016 to June 30, 2016 we applied a forfeiture rate of zero as there had been minimal forfeitures to date. Beginning July 1, 2016, we applied a forfeiture rate of six percent which is reflected in our stock-based compensation expense related to stock options for the three months ended September 30, 2016 and for the three and nine months ended September 30, 2017. In January 2017, we modified certain stock options previously granted to a former executive. The modification was made in connection with the executive’s termination. The modification included accelerated vesting of stock options to purchase 8,752 shares of common stock as well as an extension of the exercise period for all vested shares, including stock options to purchase 17,504 shares of common stock. As a result of the modification, additional stock compensation expense of $19,000 was recognized for the nine months ended September 30, 2017. There was no expense related to the modification during the three months ended September 30, 2017. For stock options paid in consideration of services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC 505-50. Non-employee stock option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these stock options, as calculated using the Black-Scholes option valuation model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of stock options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options are fully vested. Stock-based compensation expense related to stock options for consultants was $10,000 and $2,000 for the three months ended September 30, 2016 and 2017 , respectively and was $24,000 and $7,000 for the nine months ended September 30, 2016 and 2017, respectively. Stock Option Award Activity The following is a summary of our stock option activity during the nine months ended September 30, 2017 : Number of Stock Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2017 801,690 $ 5.25 $ 3.32 7.40 Granted 299,880 4.44 2.67 9.54 Exercised (27,818 ) 1.95 1.16 — Forfeited (165,192 ) 6.32 4.15 — Outstanding, September 30, 2017 908,560 $ 4.94 $ 3.06 8.23 Number of Stock Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2017 419,174 $ 5.94 $ 3.86 6.00 Vested 329,733 4.55 2.76 8.57 Exercised (27,818 ) 1.95 1.16 — Forfeited (129,901 ) 7.13 4.69 — Exercisable, September 30, 2017 591,188 $ 5.30 $ 3.32 7.98 The following table presents information related to stock options outstanding and exercisable at September 30, 2017 : Stock Options Outstanding Stock Options Exercisable Exercise Price Outstanding Number of Stock Options Weighted Average Remaining Life In Years Exercisable Number of Stock Options $1.93 – $2.00 149,000 8.35 55,884 $3.83 – $4.70 369,880 9.40 242,854 $5.06 – $6.00 250,000 6.87 192,509 $6.49 – $7.20 50,000 6.93 37,820 $7.54 – $7.55 57,800 7.21 38,202 $8.06 – $12.98 31,880 4.52 23,919 908,560 7.98 591,188 As of September 30, 2017 , there was $739,000 of unrecognized compensation expense related to unvested employee stock options, which is expected to be recognized over a weighted-average period of approximately 2.5 years . The aggregate intrinsic values of outstanding stock options and vested stock options as of September 30, 2017 were $374,000 and $151,000 , respectively, which represent options whose exercise price was less than the closing fair market value of our common stock on September 30, 2017 of $4.43 per share. Restricted Stock Units Activity We account for restricted stock units issued to employees at fair value, based on the market price of our stock on the date of grant, net of estimated forfeitures. The fair value of non-employee restricted stock units awarded are remeasured as the awards vest, and the resulting increase in fair value, if any, is recognized as expense in the period the related services are rendered. During the three months ended September 30, 2016 and 2017 we recorded $375,000 and $564,000 , respectively, of stock-based compensation related to the restricted stock unit shares that had been issued to-date. During the nine months ended September 30, 2016 and 2017 we recorded $912,000 and $1,685,000 , respectively, of stock-based compensation related to the restricted stock unit shares that had been issued to-date. Shares vested during the three months ended September 30, 2016 and 2017 were 45,653 and 79,831 , respectively. Shares vested during the nine months ended September 30, 2016 and 2017 were 222,043 and 532,031 , respectively. In January 2017, we modified certain restricted stock units previously granted to a former executive. The modification was made in connection with the executive’s termination. The modification included accelerated vesting of 8,815 units which resulted in additional stock compensation expense of $36,000 for the nine months ended September 30, 2017. There was no expense related to the modification during the three months ended September 30, 2017. A summary of restricted stock unit activity for the nine months ended September 30, 2017 is as follows: Number of Restricted Share Units Weighted- Average Grant-Date Fair Value Outstanding at January 1, 2017 1,455,558 $ 3.64 Granted 529,907 4.48 Vested (532,031 ) 4.20 Forfeited (51,741 ) 5.40 Outstanding at September 30, 2017 1,401,693 $ 4.53 As of September 30, 2017 , there was $4.3 million of unrecognized compensation expense related to unvested employee restricted stock unit agreements which is expected to be recognized over a weighted-average period of approximately 2.5 years . For restricted stock unit awards subject to graded vesting, we recognize compensation cost on a straight-line basis over the service period for the entire award. Performance Awards In August 2016, we granted 250,000 performance-based restricted stock units to an executive. The restricted stock units are subject to performance-based vesting requirements, measured quarterly, based on the average of (a) the average high daily trading price of our common stock for each trading day during the last month of the applicable calendar quarter and (b) the average low daily trading price of our common stock for each trading day during the last month of the applicable calendar quarter, each as reported by The Nasdaq Stock Market, LLC. The restricted stock units are eligible to be earned on a quarterly basis based on a linear interpolation of the applicable share price, or in the case of a liquidation event, on the day of (or in connection with) such liquidation event based on the applicable transaction price. Once earned, the restricted stock units vest 50% on the date such restricted stock units become earned and 50% on September 30, 2019 . We recognize compensation expense for restricted stock units with performance conditions using a graded vesting model, based on the probability of the performance condition being met, net of estimated pre-vesting forfeitures. The share price on the date of issuance was $5.06 per share. For the three and nine months ended September 30, 2017, we recognized $6,000 and $19,000 , respectively, of stock compensation expense in connection with this award, which is included in general and administrative expenses. Incentive Bonus Awards We provide eligible employees, including executives, the opportunity to earn bonus awards upon achievement of predetermined performance goals and objectives. The purpose is to reward attainment of company goals and/or individual performance objectives, with award opportunities expressed as a percentage of base salary. Bonuses can be measured and paid quarterly and/or annually, and are paid in cash, equity or a combination of cash and equity, in the discretion of our compensation committee. 2015 Incentive Bonus Program During 2015, our employees and executives participated in the 2015 Incentive Bonus Program. The awards under this program contained a combination of service conditions and performance conditions based on the achievement of specified performance thresholds approved by the board. The performance bonus amounts were based on each individual’s salary paid during the year multiplied by a defined bonus multiplier percentage, plus an additional 10% bonus for non-executive employees. In February 2016, upon board approval, we granted 90,265 restricted stock unit awards, of which 45,140 shares vested on the issuance date and the remaining shares vested on January 1, 2017. For the nine months ended September 30, 2016 we recorded a reduction of stock compensation expense of $21,000 in connection with the 2015 Plan which was a result of the decrease in the price of our common stock between December 31, 2015 and the date of grant. There was no expense recorded for the three months ended September 30, 2016, or for the three and nine months ended September 30, 2017, in connection with this program. 2016 Incentive Bonus Program During 2016, our employees and executives participated in the 2016 Incentive Bonus Program. The program provided for the award of annual bonuses if certain performance goals, based on revenue and certain other non-monetary targets, were attained in our 2016 fiscal year. The bonus was payable in cash, restricted stock units or a combination of cash and restricted stock units, as determined by our compensation committee, with the number of restricted stock units to be determined by dividing the dollar value to be paid in restricted stock units by the average closing price of our common stock for the ten trading days ending on the last trading day of 2016. The restricted stock units would have vested in full on the tenth business day following grant. Although the specific performance objectives were not achieved, it was determined that a discretionary bonus would be awarded under the program based on the significant achievements made toward the objectives during the year. The payment method and terms remained the same as the original bonus program. The discretionary awards were granted in February, 2017, and consisted of cash awards totaling $688,000 and equity awards in the form of restricted stock units and stock options which vested in full 10 days following grant. The equity awards consisted of 27,390 restricted stock units with a grant date fair value of $119,000 based on the grant date share price of $4.36 and 125,880 stock options with a grant date fair value of $332,000 using the Black-Scholes option valuation model using the following assumptions: stock price of $4.36 ; dividend yield of 0% ; expected volatility of 60% ; risk-free rate of 2.15% and expected life of 7 years. The total expense for these awards, $1.1 million , was recorded in the fourth quarter of 2016 and was included in accrued salaries and payroll related expenses as of December 31, 2016. The accrual was released upon payment and issuance of the awards in the first quarter of 2017. There was no expense recorded for the three or nine months ended September 30, 2016 and 2017 in connection with this program. 2017 Incentive Bonus Program During 2017, our employees and executives are participating in the 2017 Incentive Bonus Program. The program provides for the award of quarterly and annual bonuses to our employees and executive officers if certain performance goals, based on company-wide billings, expenses and certain other individual non-monetary targets, are attained in quarterly and annual performance periods during our 2017 fiscal year. The awards contain a combination of service conditions and performance conditions based on the achievement of specified performance thresholds. The awards are based on each individual’s annual salary multiplied by a bonus multiplier percentage which has been determined by our compensation committee. The plan also allows for additional discretionary awards to non-executive employees up to 10% of the total base salaries of non-executive employees. Additionally, the annual bonus, as it relates to executive employees, is subject to the achievement of certain stock price thresholds for the ten trading days ending on the last trading day of 2017. The bonuses will be paid in the form of cash, stock options, restricted stock, or a combination thereof. The number of shares underlying equity awards granted to each employee will be determined based on the performance bonus amount to be paid in equity, divided by our closing stock price on the grant date. We recognize compensation expense for the total amount of the bonuses earned during the period earned. For the three and nine months ended September 30, 2017, we recorded $193,000 and $943,000 , respectively, of compensation expense related to the 2017 performance awards as the achievement of the performance conditions was considered probable. Of the expense recorded for the three months ended September 30, 2017, $153,000 is included in research and development expenses and $40,000 is included in general and administrative expenses. Of the expense recorded for the nine months ended September 30, 2017, $584,000 is included in research and development expenses and $359,000 is included in general and administrative expenses. Common Stock Issued for Services In February 2016, we issued 3,000 shares of our common stock to a consultant in exchange for employment recruiting services. In April 2016, we issued 5,549 shares of common stock to a previous employee in connection with a separation agreement. We recorded $0 and $6,000 in stock compensation expense related to the stock issuances for the three and nine months ended September 30, 2016, respectively. The amount of compensation expense related to the consultant shares issued represents the fair value of the stock on the dates of issuance. There was no expense recorded during the three and nine months ended September 30, 2016 related to the shares issued to our previous employee as the value of those shares had been accrued at the time of separation in 2015. There was no expense related to these awards for the three and nine months ended September 30, 2017. Total equity-based compensation costs recorded in the condensed consolidated statements of operations is allocated as follows: Three Months Ended September 30, 2016 Three Months Ended September 30, 2017 Nine Months Ended September 30, 2016 Nine Months Ended September 30, 2017 Research and development Employees $ 172,000 $ 304,000 $ 497,000 $ 839,000 Non-employees 5,000 20,000 18,000 61,000 Total research and development 177,000 324,000 515,000 900,000 General and administrative Employees and directors 281,000 314,000 705,000 998,000 Non-employees 94,000 28,000 130,000 126,000 Total general and administrative 375,000 342,000 835,000 1,124,000 Total equity-based compensation $ 552,000 $ 666,000 $ 1,350,000 $ 2,024,000

RELATED PARTY TRANSACTION

RELATED PARTY TRANSACTION	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTION	RELATED PARTY TRANSACTIONS In August 2016, we entered into a consulting agreement with a member of our board of directors. Under the agreement, the board member would provide engineering design and fabrication advisory services for an hourly rate, with total payments not to exceed $120,000 during any twelve month period. During the nine months ended September 30, 2017 , we incurred expenses of $26,000 in connection with the consulting agreement. The agreement was terminated effective April 1, 2017 and there was no expense for the three months ended September 30, 2017.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Commitments —In October 2013, we signed a lease for new office space for our corporate headquarters, and moved into the new location in the first quarter of 2014. The lease had a term of 38 months and a rental cost of approximately $5,412 per month, increasing 3% annually after the first fourteen months . In addition, our share of building operating costs were estimated to be $2,101 per month. In April 2014, we amended the lease to add additional space which increased our rent to $8,286 per month beginning August 1, 2014 plus estimated monthly operating costs of $3,154 and extended the lease term through July, 2017. We had a renewal option for an additional three year term. The original lease included a tenant improvement allowance of $72,160 and the amended lease included an additional tenant improvement allowance of $38,320 . The allowances were used to construct our office build-out and have been capitalized as leasehold improvements as of December 31, 2016 and September 30, 2017 . The capitalized costs are being amortized over the amended lease term through July 2017. Effective April 2017, we amended the lease to add additional space and to extend our lease term through July 2018, with an option to extend through July 2019. With the amendment, the total leased space is now 9,024 square feet with monthly rent of $14,479 through July 2017 and $13,987 from August 1, 2017 through the end of the lease, plus estimated monthly operating costs of approximately $7,000 . In November 2013, we signed a lease for our satellite development office in Burlingame, CA. The lease had a two -year term, and rental costs of approximately $4,000 per month. In May 2015, we renewed the lease for a one year period expiring November 30, 2016 with rental costs of $5,000 per month. Effective December 16, 2016, we signed a new lease of 5,248 square feet of office space within the same building in Burlingame, California commencing February 2017. The lease has a five year term, and rental costs of approximately $17,000 per month. Rent expense related to our facilities and equipment for the three months ended September 30, 2016 and 2017 was $57,000 and $127,000 , respectively and for the nine months ended September 30, 2016 and 2017, was $152,000 and $339,000 , respectively. Legal Proceedings — W e are occasionally involved in legal proceedings and other matters arising from the normal course of business. Beginning on March 17, 2015, three putative class action lawsuits were filed in the United States District Court for the Central District of California, naming us, Terry Lingren and John Philpott as defendants. The three lawsuits were consolidated into a single putative class action, In re Resonant Inc. Securities Litigation, Case No. 15-cv-01970 SJO (MRWx). On February 23, 2016, the plaintiffs filed a consolidated second amended complaint, purporting to assert claims under the federal securities laws against us, Terry Lingren, John Philpott, and the underwriter of our May 29, 2014 IPO. In the consolidated second amended complaint, the plaintiffs purport to be acting on behalf of a class consisting of purchasers or acquirers of our common stock between November 6, 2014 and April 2, 2015, as well as a class of persons or entities who purchased or acquired our shares in (or traceable to) our IPO. The plaintiffs alleged that, as a result of the defendants’ allegedly false and/or misleading statements and/or omissions concerning our business, operations, prospects and performance, our common stock traded at artificially inflated prices between November 6, 2014 and April 2, 2015. On July 11, 2016, the court entered an order granting in part and denying in part our motion to dismiss the consolidated second amended complaint. The court granted our motion to dismiss with respect to plaintiffs’ claims under Section 11 of the Securities Act of 1933 and Section 20(a) of the Securities Exchange Act of 1934. The court also granted our motion to dismiss plaintiffs’ claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder to the extent those claims are premised on alleged misstatements made on February 26, 2015. The court denied our motion to dismiss with respect to plaintiffs’ claims under Section 15 of the Securities Act of 1933, and with respect to plaintiffs’ claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder to the extent those claims are premised on alleged misstatements made in November and December of 2014 and January of 2015. On October 26, 2016, the court issued an order clarifying its July 11, 2016 order on our motion to dismiss, making clear that the court's actual intent was to grant the motion to dismiss with respect to the claims under Section 15 of the Securities Act of 1933, while denying the motion to dismiss with respect to the claims under Section 20(a) of the Securities Exchange Act of 1934. The parties in the putative class action have reached a settlement that, if approved by the court, will fully resolve plaintiffs’ claims and provide for the release of all claims asserted in the litigation. The settlement amount will be paid by our insurance carrier. On July 13, 2017, the court entered an order granting preliminary approval of the settlement. The court has scheduled a final approval hearing to take place on November 20, 2017. We can make no assurances that the court will grant final approval of the settlement. On September 24, 2015, a purported shareholder derivative action was filed in the United States District Court for the Central District of California, and is pending before the same federal district court judge to whom the putative class action has been assigned. In the derivative action, the plaintiffs allege that certain of our officers and directors breached their fiduciary duties to us, including by allegedly violating the federal securities laws and exposing us to possible financial liability. On November 16, 2015, the court entered an order staying the proceedings in the shareholder derivative action pending certain further developments. The court has set a status conference to take place on December 4, 2017. We have reached an agreement in principle to settle the shareholder derivative action. The settlement is in the process of being documented so that it may be presented to the court for approval. We can make no assurances that the settlement will be consummated or that the court will approve it. We intend to continue to defend ourselves vigorously in these actions. We are not party to any other legal proceedings. We may, from time to time, be party to litigation and subject to claims incident to the ordinary course of business. As our growth continues, we may become party to an increasing number of litigation matters and claims. The outcome of litigation and claims cannot be predicted with certainty, and the resolution of any future matters could materially affect our future financial position, results of operations or cash flows. We have directors’ and officers’ liability insurance, which will be utilized in the defense of these matters. The liability insurance may not cover all of the future liabilities we may incur in connection with the foregoing matters. As of September 30, 2017 , we have incurred total legal expenses of approximately $750,000 which is the maximum of our insurance deductible. Legal fees and other costs associated with such actions are expensed as incurred. We assess, in conjunction with our legal counsel, the need to record a liability for litigation and contingencies. Litigation accruals are recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. Material loss contingencies that are reasonably possible of occurrence, if any, are subject to disclosure. With respect to the litigation referred to above, we estimate that we are insured for all or substantially all of the amount of possible loss that might result from an adverse judgment or a settlement of these matters. We will evaluate developments in legal proceedings and other matters on a quarterly basis. As of September 30, 2016 and September 30, 2017 , there was no litigation or contingency with at least a reasonable possibility of a material loss. No losses have been recorded during the nine months ended September 30, 2016 and September 30, 2017 , respectively, with respect to litigation or loss contingencies.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On October 2, 2017, we completed the second of two closings related to the private placement sale of an aggregate of 1,976,919 units at a price of $4.70 per unit to institutional and individual investors. Each unit consists of one share of our common stock and one warrant to purchase one share of our common stock at an exercise price of $4.85 per share for a period commencing six months and ending three years from the date of the initial closing of the offering. Gross proceeds in the second closing, for 231,338 units, were $1.1 million and net proceeds after deducting placement agent fees and offering expenses were $1.0 million . In the second closing we issued to the placement agent in the financing, warrants to purchase an aggregate of 11,567 shares of our common stock at an exercise price of $4.85 for a period commencing six months and ending three years from the date of the initial closing of the offering. The first closing, for 1,745,581 units, occurred on September 28, 2017. (See Note 5 - Stockholders' Equity)

SUMMARY OF SIGNIFICANT ACCOUN16

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates —The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. In the opinion of management, all adjustments (consisting of normal accruals) considered for a fair presentation have been included. Significant estimates made in preparing these financial statements include (a) assumptions to calculate the fair values of financial instruments, warrants and equity instruments and other liabilities and the deferred tax asset valuation allowance and (b) the useful lives for depreciable and amortizable assets. Actual results could differ from those estimates. In the opinion of management, all adjustments, including normal recurring accruals considered necessary for a fair presentation, have been included.
Restricted Cash	Restricted Cash —Restricted cash at December 31, 2016 and September 30, 2017 represents cash held within a certificate of deposit with a financial institution, which serves as collateral for our corporate credit cards. The restriction on the cash will lapse in conjunction with the expiration of the use of the corporate credit cards.
Investments	Investments —Securities held-to-maturity: Management determines the appropriate classification of investments at the time of purchase and reevaluates such designation as of each balance sheet date. Investment securities are classified as held-to-maturity when we have the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization is included in investment income. Interest on securities classified as held-to-maturity is included in investment income. When the fair value of an investment instrument classified as held-to-maturity is less than its amortized cost, management assesses whether or not: (i) we have the intent to sell the instrument or (ii) it is more likely than not that we will be required to sell the instrument before its anticipated recovery. If either of these conditions is met, we must recognize an other-than-temporary impairment for the difference between the instrument’s amortized cost basis and its fair value, and include such amounts in net securities gains (losses). For investment instruments that do not meet the above criteria and are not expected to be recovered at the amortized cost basis, the instrument is considered other-than-temporarily impaired. For these instruments, we separate the total impairment into the credit loss component and the amount of the loss related to other factors. In order to determine the amount of the credit loss, we calculate the recovery value by performing a discounted cash flow analysis based on the current cash flows and future cash flows management expects to recover. The discount rate is the effective interest rate implicit in the underlying instrument. The amount of the total other-than-temporary impairment related to credit loss is recognized in earnings and is included in net securities gains (losses). The amount of the total other-than-temporary impairment related to other factors is recognized in other comprehensive income. For investment instruments that have other-than-temporary impairment recognized through earnings, if through subsequent evaluation there is a significant increase in the cash flow expected, the difference between the amortized cost basis and the cash flows expected to be collected is accreted as interest income.
Fair Value of Financial Instruments	Fair Value of Financial Instruments —We measure certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The carrying amounts of our financial instruments, including cash equivalents, restricted cash, investments held-to-maturity, accounts payable, and accrued liabilities, approximate fair value due to their short maturities.
Property and Equipment	Property and Equipment —Property and equipment consists of leasehold improvements associated with our offices, software purchased during the normal course of business, equipment and office furniture and fixtures, all of which are recorded at cost. In July 2016, other property and equipment were acquired as part of the purchase of GVR and were initially recorded at their fair value. Depreciation and amortization is recorded using the straight-line method over the respective useful lives of the assets ranging from three to five years. Leasehold improvements are amortized over the shorter of lease term or useful life. Long-lived assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable.
Intangible Assets Subject to Amortization	Intangible Assets, net —Intangible assets are recorded at cost and amortized over the useful life. In the case of business combinations, intangible assets are recorded at fair value. At December 31, 2016 and September 30, 2017 , intangible assets, net, includes patents and a domain name and other intangible assets purchased as part of our acquisition of GVR, including customer relationships, technology and a trademark. Intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable.
Goodwill	Goodwill— At September 30, 2017 , goodwill represents the difference between the price paid to acquire GVR and the fair value of the assets acquired, net of assumed liabilities. We review goodwill for impairment annually and whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable.
Revenue Recognition	Revenue Recognition —Revenue consists primarily of fees received in connection with filter design projects with customers. Contracts may involve upfront non-refundable fees, intended to support our initial engineering product development efforts, as well as milestone payments based upon the successful completion of certain deliverables. In relation to the upfront non-refundable fees, we recognize revenue in accordance with the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 605, Revenue Recognition. We recognize revenue as the services are performed over the initial engineering filter design development period and when all of the following criteria have been met: persuasive evidence of an arrangement exists, services have been rendered, collection of the revenue is reasonably assured, and the fees are fixed or determinable. We record the expenses related to these projects in the periods incurred and they are generally included in research and development expense. In addition to upfront non-refundable payments, the filter design projects may include certain milestone payments upon successful filter design or a design stage completion. These filter design projects are associated with complex technology development, and as such we do not have certainty about our ability to achieve the program milestones. Achievement of the milestone is generally dependent on the filter design specifications and the milestone typically needs to be accepted by the customer. The payment associated with achieving the milestone is generally commensurate with our effort or the value of the deliverable and is generally non-refundable. We record revenue associated with the milestone payments in accordance with ASC Topic 605-28 Milestone Method whereby we record revenue upon successful completion of the related milestone and when collection of the revenue is reasonably assured.
Research and Development	Research and Development —Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with ASC Topic 730-10, Research and Development .
Stock-Based Compensation	Stock-Based Compensation —We account for employee stock options in accordance with ASC Topic 718, Compensation-Stock Compensation . For stock options issued to employees and directors we use the Black-Scholes option valuation model for estimating fair value at the date of grant. For stock options issued for services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC Topic 505-50 , Equity , or ASC 505-50, as amended. Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these options, as calculated using the Black-Scholes option valuation model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options or warrants are fully vested. We account for restricted stock units issued to employees at fair value, based on the market price of our stock on the date of grant, net of estimated forfeitures. Compensation expense is recognized for the portion of the award that is ultimately expected to vest over the period during which the recipient renders the required services to the Company generally using the straight-line single option method. The fair value of non-employee restricted stock units awarded are remeasured as the awards vest, and the resulting increase or decrease in fair value, if any, is recognized as an increase or decrease to compensation expense in the period the related services are rendered.
Earnings Per Share, or EPS	Earnings Per Share, or EPS —EPS is computed in accordance with ASC Topic 260, Earnings per Share , and is calculated using the weighted average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents unless the effect is to reduce a loss or increase the income per share. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method), the exercise of warrants (using the if-converted method) and the vesting of restricted stock unit awards.
Income Taxes	Income Taxes —We account for income taxes in accordance with ASC Topic 740, Income Taxes , or ASC 740, which requires the recognition of deferred tax assets and liabilities for the future consequences of events that have been recognized in our condensed consolidated financial statements or tax returns. The measurement of the deferred items is based on enacted tax laws. In the event the future consequences of differences between financial reporting bases and the tax bases of our assets and liabilities result in a deferred tax asset, ASC 740 requires an evaluation of the probability of being able to realize the future benefits indicated by such asset. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion or the entire deferred tax asset will not be realized. As part of the process of preparing our consolidated financial statements, we are required to estimate our income tax expense in each of the jurisdictions in which we operate. We also assess temporary differences resulting from differing treatment of items for tax and accounting differences. We record a valuation allowance to reduce the deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. For the period when we were organized as a limited liability company, we were treated as a partnership for federal and state income tax purposes under the entity classification domestic default rules. As of December 31, 2016 and September 30, 2017 , no liability for unrecognized tax benefits was required to be reported. We recognize interest and penalties related to income tax matters in income taxes, and there were none for the three and nine months ended September 30, 2016 and September 30, 2017 , respectively. We have filed, or are in the process of filing, tax returns that are subject to audit by the respective tax authorities. Although the ultimate outcome would be unknown, we believe that any adjustments that may result from tax return audits are not likely to have a material, adverse effect on our condensed consolidated results of operations, financial position or cash flows.
Foreign Currency Remeasurement	Foreign Currency Translation —The Swiss Franc has been determined to be the functional currency for the net assets of our Swiss-based subsidiary. We translate the assets and liabilities to U.S. dollars at each reporting period using exchange rates in effect at the balance sheet date and record the effects of the foreign currency translation in accumulated other comprehensive income (loss) in shareholders' equity. We translate the income and expenses to U.S. dollars at each reporting period using the average exchange rate in effect for the period and record the effects of the foreign currency translation as other comprehensive income (loss) in the consolidated statements of comprehensive loss. Gains and losses resulting from foreign currency transactions are included in net loss in the consolidated statements of comprehensive loss.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Revenue from Contracts with Customers— In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) . The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , which defers the effective date of ASU No. 2014-09 for all entities by one year to annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. This ASU shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. Early adoption is permitted but not before the annual periods beginning after December 15, 2016, including interim periods within that reporting period. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net) . This ASU provides further guidance surrounding the recognition of revenue as well as guidance involving principal versus agent considerations. The effective date of this ASU is the same as ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing . This amendment provides clarification surrounding the identification of performance obligations and offers licensing implementation guidance. The effective date of this ASU is the same as ASU 2014-09. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606), Narrow-Scope Improvements and Practical Expedients, which provides further guidance surrounding certain aspects of ASU 2014-09. The effective date of this ASU is the same as ASU 2014-09. The new standards will become effective for us on January 1, 2018 and we plan to adopt at that time. We have reviewed our contracts which we believe will be impacted by the adoption and we have decided to adopt the standard using the modified retrospective approach with a cumulative effect of the initial application recognized at the date of adoption. We do not believe the adoption of this guidance will have a significant impact on our consolidated balance sheet, statement of comprehensive loss or statement of cash flow due to the relatively small number of contracts and nature of our contracts, which are primarily related to design development projects where we believe the revenue will be recognized over time, which is consistent with the current method of revenue recognition. Leases— In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , a comprehensive new leases standard that amends various aspects of existing accounting guidance for leases. It will require recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The main difference between previous U.S. GAAP and the amended standard is the recognition of lease assets and lease liabilities by lessees on the balance sheet for those leases classified as operating leases under previous U.S. GAAP. The accounting applied by a lessor is largely unchanged from that applied under previous U.S. GAAP. As a result, we will have to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing our right to use the underlying asset for the lease term on the balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We are currently reviewing the two leases we have and are evaluating the effects of the new guidance on our consolidated financial statements. We expect to report additional assets and liabilities related to these leases as a result of the new guidance, however, we do not expect it to have a material impact on our consolidated financial statements. Intangibles-Goodwill and Other— In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which simplifies the accounting for goodwill impairments by eliminating step 2 from the goodwill impairment test. The amended guidance will become effective for us commencing in the first quarter of fiscal 2019. We are currently evaluating the impact of this new standard. Compensation-Stock Compensation— In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , which provides clarity over the accounting for a change to the terms or conditions of a share-based payment award. The amendments in the update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The amendments in this update should be applied prospectively to an award modification on or after the adoption date. We plan to early adopt this guidance if, and when, we experience a share-based award modification.

SUMMARY OF SIGNIFICANT ACCOUN17

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Schedule of number of anti-dilutive shares excluded from the calculation of diluted net loss per share attributable to common stockholders	The following table presents the number of shares excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods below: Nine Months Ended September 30, 2016 2017 Common stock warrants 3,017,159 6,202,147 Common stock options 753,114 908,560 Non-vested restricted stock unit awards 874,075 1,401,693 Total shares excluded from net loss per share attributable to common stockholders 4,644,348 8,512,400

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2017
Warrants and Rights Note Disclosure [Abstract]
Schedule of warrant activity	A roll-forward of warrant share activity from January 1, 2016 to September 30, 2016 is shown in the following table: Issued and Outstanding Warrants as of January 1, 2016 Warrants Issued Warrants Exercised/ Expired Issued and Outstanding Warrants as of September 30, 2016 Bridge Warrants 249,999 — — 249,999 Consulting Warrants 117,778 — (19,778 ) (1) 98,000 Financing Warrants 78,186 — — 78,186 Underwriting Warrants 310,500 — — 310,500 IR Consulting Warrants 48,000 — — 48,000 Private Placement Warrants — 2,096,724 2,096,724 Underwriting Warrants- Public Offering 2016 135,750 135,750 804,463 2,232,474 (19,778 ) 3,017,159 (1) During the nine months ended September 30, 2016 there were 19,778 common stock warrants that were exercised through a cashless exercise which resulted in 19,693 shares being issued. A roll-forward of warrant share activity from January 1, 2017 to September 30, 2017 is shown in the following table: Issued and Outstanding Warrants as of January 1, 2017 Warrants Issued Warrants Exercised/ Expired Issued and Outstanding Warrants as of September 30, 2017 Bridge Warrants 249,999 — — 249,999 Consulting Warrants 98,000 — (41,889 ) (1) 56,111 Financing Warrants 78,186 — — 78,186 Underwriting Warrants 310,500 — — 310,500 IR Consulting Warrants 48,000 — (42,000 ) (2) 6,000 Private Placement Warrants - 2016 1,995,124 — (89,281 ) (3) 1,905,843 Underwriting Warrants - Public Offering 2016 135,750 — — 135,750 Private Placement Warrants - February 2017 — 1,626,898 — 1,626,898 Private Placement Warrants - September 2017 — 1,832,860 — 1,832,860 2,915,559 3,459,758 (173,170 ) 6,202,147 (1) During the nine months ended September 30, 2017 , there were 41,889 common stock warrants that were exercised through cashless exercises which resulted in 41,800 shares being issued. (2) During the nine months ended September 30, 2017, 42,000 warrants expired. (3) During the nine months ended September 30, 2017, there were 89,281 common stock warrants that were exercised through cashless exercises which resulted in 37,031 shares being issued.

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of fair values of stock options granted, estimated using Black-Scholes option valuation model assumptions	We estimated the fair value of stock options awarded during the nine months ended September 30, 2016 and 2017 using the Black-Scholes option valuation model. The fair values of stock options granted for the periods were estimated using the following assumptions: Stock Option Grants Awarded During the Nine Months Ended September 30, 2016 Stock Option Grants Awarded During the Nine Months Ended September 30, 2017 Stock Price $1.93 to $5.26 $4.36 to $4.68 Dividend Yield 0.00% 0.00% Expected Volatility 60% 60% Risk-free interest rate 1.30% - 1.78% 1.95% - 2.14% Expected Life 7 years 7 years
Summary of stock option activity	The following is a summary of our stock option activity during the nine months ended September 30, 2017 : Number of Stock Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2017 801,690 $ 5.25 $ 3.32 7.40 Granted 299,880 4.44 2.67 9.54 Exercised (27,818 ) 1.95 1.16 — Forfeited (165,192 ) 6.32 4.15 — Outstanding, September 30, 2017 908,560 $ 4.94 $ 3.06 8.23 Number of Stock Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2017 419,174 $ 5.94 $ 3.86 6.00 Vested 329,733 4.55 2.76 8.57 Exercised (27,818 ) 1.95 1.16 — Forfeited (129,901 ) 7.13 4.69 — Exercisable, September 30, 2017 591,188 $ 5.30 $ 3.32 7.98
Schedule of information related to stock options outstanding and exercisable	The following table presents information related to stock options outstanding and exercisable at September 30, 2017 : Stock Options Outstanding Stock Options Exercisable Exercise Price Outstanding Number of Stock Options Weighted Average Remaining Life In Years Exercisable Number of Stock Options $1.93 – $2.00 149,000 8.35 55,884 $3.83 – $4.70 369,880 9.40 242,854 $5.06 – $6.00 250,000 6.87 192,509 $6.49 – $7.20 50,000 6.93 37,820 $7.54 – $7.55 57,800 7.21 38,202 $8.06 – $12.98 31,880 4.52 23,919 908,560 7.98 591,188
Schedule of restricted stock unit activity	A summary of restricted stock unit activity for the nine months ended September 30, 2017 is as follows: Number of Restricted Share Units Weighted- Average Grant-Date Fair Value Outstanding at January 1, 2017 1,455,558 $ 3.64 Granted 529,907 4.48 Vested (532,031 ) 4.20 Forfeited (51,741 ) 5.40 Outstanding at September 30, 2017 1,401,693 $ 4.53
Schedule of stock-based compensation	Total equity-based compensation costs recorded in the condensed consolidated statements of operations is allocated as follows: Three Months Ended September 30, 2016 Three Months Ended September 30, 2017 Nine Months Ended September 30, 2016 Nine Months Ended September 30, 2017 Research and development Employees $ 172,000 $ 304,000 $ 497,000 $ 839,000 Non-employees 5,000 20,000 18,000 61,000 Total research and development 177,000 324,000 515,000 900,000 General and administrative Employees and directors 281,000 314,000 705,000 998,000 Non-employees 94,000 28,000 130,000 126,000 Total general and administrative 375,000 342,000 835,000 1,124,000 Total equity-based compensation $ 552,000 $ 666,000 $ 1,350,000 $ 2,024,000

ORGANIZATION AND DESCRIPTION 20

ORGANIZATION AND DESCRIPTION OF BUSINESS (Liquidity and Capital Resources) (Details) - USD ($) shares in Thousands	1 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Class of Stock [Line Items]
Accumulated deficit	$ 59,500,000	$ 59,500,000		$ 46,159,000
Existing cash balances and investments	13,500,000	13,500,000
Net proceeds from the sale of common stock from private placement offering		15,025,000	$ 5,177,000
Cash used per quarter		11,300,000
Shelf registration statement, public offerings, maximum aggregate proceeds	35,000,000	35,000,000
Net proceeds from units issued in the period	7,500,000	15,025,000
Capital Units
Class of Stock [Line Items]
Net proceeds from units issued in the period		$ 11,500,000
New shares issued		2,715
Value of capital shares reserve for future issuance	$ 23,500,000	$ 23,500,000

SUMMARY OF SIGNIFICANT ACCOUN21

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)financial_institution	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)financial_institution	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)
Concentration Risks, Types, No Concentration Percentage [Abstract]
Number of financial institutions where the Company holds checking deposits | financial_institution	1		1
Revenue Recognition [Abstract]
Revenue recognized	$ 106,000		$ 482,000
Deferred revenue, current	261,000		261,000		$ 279,000
Income Taxes
Income tax penalties and interest accrued	0		0		$ 0
Income tax penalties and interest expense	0	$ 0
Minimum
Property and Equipment
Useful life (in years)			3 years
Maximum
Property and Equipment
Useful life (in years)			5 years
Certificates of Deposit | Foreign Debt Securities
Investments
Investment income	$ 14,000	$ 4,000	$ 39,000	$ 10,000

SUMMARY OF SIGNIFICANT ACCOUN22

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Anti-Dilutive Shares Excluded from Calculation or EPS) (Details) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share, or EPS
Number of anti-dilutive shares excluded from the calculation of diluted net loss per share attributable to common stockholders	8,512,400	4,644,348
Common stock warrants
Earnings Per Share, or EPS
Number of anti-dilutive shares excluded from the calculation of diluted net loss per share attributable to common stockholders	6,202,147	3,017,159
Common stock options
Earnings Per Share, or EPS
Number of anti-dilutive shares excluded from the calculation of diluted net loss per share attributable to common stockholders	908,560	753,114
Restricted stock units
Earnings Per Share, or EPS
Number of anti-dilutive shares excluded from the calculation of diluted net loss per share attributable to common stockholders	1,401,693	874,075

ACQUISITION OF GVR TRADE S.A. (

ACQUISITION OF GVR TRADE S.A. (Details) - GVR Trade S.A. - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Jul. 06, 2016	Dec. 31, 2016
Business Acquisition [Line Items]
Payments to acquire business gross	$ 661
Value of common stock issued	$ 545
Common stock shares issued, share price (in usd per share)	$ 4.36
Consideration Transferred	$ 1,200
Acquisition related costs		$ 92
Goodwill acquired	$ 800
Common Stock
Business Acquisition [Line Items]
Number of shares	125

WARRANTS (Narrative) (Details)

WARRANTS (Narrative) (Details) - USD ($)	Sep. 28, 2017	Feb. 22, 2017	Sep. 30, 2017	Feb. 28, 2017	Sep. 30, 2017
Capital Units
Warrant liabilities
New shares issued					2,715,000
Capital Units | Investor
Warrant liabilities
Warrant share price (in dollars per share)		$ 4.61
Capital Units | Placement Agent
Warrant liabilities
Warrant share price (in dollars per share)	$ 4.85
Capital Units | Private Placement Warrants | Investors, Executives and Board Members
Warrant liabilities
Exercise price (in dollars per unit/share)			$ 4.85	$ 8.25	$ 4.85
Common stock warrants | Investor
Warrant liabilities
Warrant term, period start after closing		6 months
Warrant term, period end after closing		30 months		30 months
Common stock warrants | Investors, Executives and Board Members
Warrant liabilities
Warrant term, period start after closing			6 months
Warrant term, period end after closing			36 months
Common stock warrants | Placement Agent
Warrant liabilities
Warrant term, period start after closing	6 months			6 months
Warrant term, period end after closing	3 years
Private Placement Warrants - 2016 | Private Placement Warrants
Warrant liabilities
Warrants to purchase shares of common stock (in unit/shares)			1,745,581	1,626,898	1,745,581
Private Placement Warrants - 2016 | Capital Units | Private Placement Warrants | Investor
Warrant liabilities
New shares issued		1,626,898		1,626,898
Private Placement Warrants - 2016 | Capital Units | Private Placement Warrants | Investors, Executives and Board Members
Warrant liabilities
New shares issued			1,832,860
Private Placement Warrants - 2016 | Capital Units | Private Placement Warrants | Placement Agent
Warrant liabilities
New shares issued	98,846
Investor Relations | Private Placement Warrants
Warrant liabilities
Warrant fair value			$ 3,200,000	$ 2,100,000
Warrant share price (in dollars per share)			$ 4.49	$ 4.91	$ 4.49
Expected term			3 years	3 years
Expected volatility rate			60.00%	60.00%
Expected dividend rate			0.00%	0.00%
Risk free interest rate			1.59%	1.50%

WARRANTS (Warrant Share Activit

WARRANTS (Warrant Share Activity) (Details) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	2,915,559	804,463
Warrants Issued	3,459,758	2,232,474
Warrants Exercised/Expired	(173,170)	(19,778)
Balance at the end of the period (in warrants)	6,202,147	3,017,159
Exercise of warrants, cashless (in shares)		19,693
Bridge Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	249,999	249,999
Warrants Issued	0	0
Warrants Exercised/Expired	0	0
Balance at the end of the period (in warrants)	249,999	249,999
Consulting Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	98,000	117,778
Warrants Issued	0	0
Warrants Exercised/Expired	(41,889)	(19,778)
Balance at the end of the period (in warrants)	56,111	98,000
Exercise of warrants, cashless (in shares)	41,800
Financing Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	78,186	78,186
Warrants Issued	0	0
Warrants Exercised/Expired	0	0
Balance at the end of the period (in warrants)	78,186	78,186
Underwriting Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	310,500	310,500
Warrants Issued	0	0
Warrants Exercised/Expired	0	0
Balance at the end of the period (in warrants)	310,500	310,500
IR Consulting Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	48,000	48,000
Warrants Issued	0	0
Warrants Exercised/Expired	(42,000)	0
Balance at the end of the period (in warrants)	6,000	48,000
Private Placement Warrants - 2016
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	1,995,124
Warrants Issued	0
Warrants Exercised/Expired	(89,281)
Balance at the end of the period (in warrants)	1,905,843
Underwriting Warrants - Public Offering 2016
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	135,750
Warrants Issued	0	135,750
Warrants Exercised/Expired	0
Balance at the end of the period (in warrants)	135,750	135,750
Private Placement Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)		0
Warrants Issued		2,096,724
Warrants Exercised/Expired
Balance at the end of the period (in warrants)		2,096,724
Exercise of warrants, cashless (in shares)	37,031
Private Placement Warrants - February 2017
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	0
Warrants Issued	1,626,898
Warrants Exercised/Expired	0
Balance at the end of the period (in warrants)	1,626,898
Private Placement Warrants - September 2017
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	0
Warrants Issued	1,832,860
Warrants Exercised/Expired	0
Balance at the end of the period (in warrants)	1,832,860
Common stock warrants
Roll forward of warrant activity
Warrants Exercised/Expired		(19,778)
Options Exercised, Cashless | Private Placement Warrants
Roll forward of warrant activity
Warrants Exercised/Expired	(89,281)

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - USD ($)	Oct. 02, 2017	Sep. 28, 2017	Feb. 22, 2017	Sep. 30, 2017	Feb. 28, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Class of Stock [Line Items]
Common stock, shares authorized				47,000,000		47,000,000		47,000,000
Proceeds from the sale of common stock from private placement offering						$ 15,025,000	$ 5,177,000
Net proceeds from units issued in the period				$ 7,500,000		15,025,000
Shelf registration statement, public offerings, maximum aggregate proceeds				$ 35,000,000		$ 35,000,000
Preferred stock, shares authorized				3,000,000		3,000,000		3,000,000
Capital Units
Class of Stock [Line Items]
New shares issued						2,715,000
Net proceeds from units issued in the period						$ 11,500,000
Value of capital shares reserve for future issuance				$ 23,500,000		$ 23,500,000
Investor | Capital Units
Class of Stock [Line Items]
Share price (in dollars per share)			$ 4.61
Proceeds from the sale of common stock from private placement offering			$ 7,500,000
Net proceeds from units issued in the period			$ 29,000
Investor | Common stock warrants
Class of Stock [Line Items]
Warrant exercise price			$ 8.25
Warrant term, period start after closing			6 months
Warrant term, period end after closing			30 months		30 months
Institutional and Individual Investors | Capital Units
Class of Stock [Line Items]
Share price (in dollars per share)		$ 4.70
Institutional and Individual Investors | Common stock warrants
Class of Stock [Line Items]
Warrant exercise price		$ 4.85
Warrant term, period end after closing		3 years
Placement Agent | Capital Units
Class of Stock [Line Items]
Share price (in dollars per share)		$ 4.85
Placement Agent | Common stock warrants
Class of Stock [Line Items]
Warrant term, period start after closing		6 months			6 months
Warrant term, period end after closing		3 years
Private Placement Warrants - 2016 | Private Placement Warrants | Investor | Capital Units
Class of Stock [Line Items]
New shares issued			1,626,898		1,626,898
Private Placement Warrants - 2016 | Private Placement Warrants | Institutional and Individual Investors | Capital Units
Class of Stock [Line Items]
New shares issued		1,976,919
Private Placement Warrants - 2016 | Private Placement Warrants | Placement Agent | Capital Units
Class of Stock [Line Items]
New shares issued		98,846
Private Placement, Offering One | Institutional and Individual Investors | Capital Units
Class of Stock [Line Items]
Sold in private placement		1,745,581
Proceeds from the sale of common stock from private placement offering		$ 8,200,000
Proceeds from issuance of private placement, net of offering costs		$ 7,500,000
Subsequent Event | Placement Agent | Common stock warrants
Class of Stock [Line Items]
Warrant term, period end after closing	3 years
Subsequent Event | Private Placement, Offering One | Placement Agent | Common stock warrants
Class of Stock [Line Items]
Sold in private placement	87,279
Subsequent Event | Private Placement, Offering Two | Institutional and Individual Investors | Capital Units
Class of Stock [Line Items]
Sold in private placement	231,338
Proceeds from the sale of common stock from private placement offering	$ 1,100,000
Proceeds from issuance of private placement, net of offering costs	$ 1,000,000
Subsequent Event | Private Placement, Offering Two | Placement Agent | Common stock warrants
Class of Stock [Line Items]
Sold in private placement	11,567

STOCK-BASED COMPENSATION (Narra

STOCK-BASED COMPENSATION (Narrative) (Details)	Sep. 30, 2019	Aug. 08, 2016	Jun. 30, 2017shares	Feb. 28, 2017USD ($)$ / sharesshares	Jan. 31, 2017shares	Aug. 31, 2016shares	Jun. 30, 2016shares	Feb. 29, 2016shares	Sep. 30, 2017USD ($)quarter$ / sharesshares	Sep. 30, 2016USD ($)quarter$ / sharesshares	Sep. 30, 2017USD ($)quarter$ / sharesshares	Sep. 30, 2016USD ($)quarter$ / sharesshares	Dec. 31, 2016USD ($)	Apr. 30, 2016shares	Jan. 31, 2014shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested (in shares) | shares											125,880
Remaining nonvested, number of Shares | shares									82,500		82,500
Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares									131,500	55,000	299,880	291,500
Vested (in shares) | shares											329,733
Unrecognized compensation expense related to unvested employee stock option									$ 739,000		$ 739,000
Options outstanding, aggregate intrinsic value									374,000		374,000
Options vested, aggregate intrinsic value									$ 151,000		$ 151,000
Weighted average period											2 years 6 months 18 days
Granted (in dollars per share) | $ / shares											$ 4.44
Share price (in dollars per share) | $ / shares									$ 4.43		$ 4.43
Dividend Yield											0.00%	0.00%
Expected Volatility											60.00%	60.00%
Expected Life											7 years	7 years
Common stock options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share) | $ / shares									4.36	$ 1.93	$ 4.36	$ 1.93
Risk-free interest rate											1.95%	1.30%
Common stock options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share) | $ / shares									$ 4.68	$ 5.26	$ 4.68	$ 5.26
Risk-free interest rate											2.14%	1.78%
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation									$ 564,000	$ 375,000	$ 1,685,000	$ 912,000
Unrecognized compensation expense related to unvested employee stock option									$ 4,300,000		$ 4,300,000
Weighted average period											2 years 6 months 7 days
Granted (in shares) | shares											529,907
Vested (in shares) | shares									79,831		532,031	222,043
Granted (in dollars per share) | $ / shares											$ 4.48
Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance bonus amount, percent of estimate									10.00%
2014 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock approved for issuance | shares									5,950,000		5,950,000				1,400,000
Number of additional shares authorized | shares			3,250,000				1,300,000
2015 Performance Plan | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in dollars per share) | $ / shares											$ 5.06
2015 Incentive Bonus Program | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation											$ 21,000
Granted (in shares) | shares								90,265
Vested (in shares) | shares								45,140
Employees and Consultants | Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower limit (in dollars per share) | $ / shares											$ 4.36
Exercise price range, upper limit (in dollars per share) | $ / shares											$ 4.68
Term of award											10 years
Aggregate grant date fair value of options granted									$ 356,000		$ 802,000
Employees | Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower limit (in dollars per share) | $ / shares												$ 1.93
Exercise price range, upper limit (in dollars per share) | $ / shares												$ 5.26
Term of award												10 years
Number of quarters over which awards vest, grant date subsequent to initial vesting | quarter									16	16	16	16
Aggregate grant date fair value of options granted										$ 166,000		$ 467,000
Stock compensation									$ 157,000	100,000	$ 332,000	420,000
Forfeitures rate											6.00%
Consultants | Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation									10,000	2,000	$ 7,000	24,000
Non-executive employees | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Bonus percentage											10.00%
Executives | Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Accelerated vesting, number of shares impacted | shares					8,752
Option exercise period extended, number of shares impacted | shares					17,504
Plan modification, incremental compensation cost									0		$ 19,000
Executives | Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Accelerated vesting, number of shares impacted | shares					8,815
Plan modification, incremental compensation cost									0		36,000
Executives | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares						250,000
Award vesting rights, percent		50.00%
Executives | Performance Based Awards | Maximum | Forecast
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percent	50.00%
Common Stock | 2015 Performance Plan | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation									6,000		$ 19,000
Common Stock | 2016 Incentive Bonus Program | Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares				125,880
Common Stock | 2016 Incentive Bonus Program | Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares				27,390
Granted in the period, grant date intrinsic value				$ 119,000
Granted (in dollars per share) | $ / shares				$ 4.36
Common Stock | 2016 Incentive Bonus Program | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate grant date fair value of options granted				$ 688,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period											10 days
Stock compensation									0	0	$ 0	0	$ 1,100,000
Grant date fair value				$ 332,000
Share price (in dollars per share) | $ / shares				$ 4.36
Dividend Yield				0.00%
Expected Volatility				60.00%
Risk-free interest rate				2.15%
Expected Life				7 years
Common Stock | 2017 Incentive Bonus Program | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period											10 days
Stock compensation											$ 943,000
Common Stock | Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation									193,000	$ 0		$ 6,000
Common stock issued (in shares) | shares								3,000						5,549
Research and development expenses | Common Stock | 2017 Incentive Bonus Program | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation									153,000		584,000
General and administrative expenses | Common Stock | 2017 Incentive Bonus Program | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation									$ 40,000		$ 359,000

STOCK-BASED COMPENSATION (Estim

STOCK-BASED COMPENSATION (Estimated Fair Value of Stock Options) (Details) - Common stock options - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)	$ 4.43
Dividend Yield	0.00%	0.00%
Expected Volatility	60.00%	60.00%
Expected Life	7 years	7 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)	$ 4.36	$ 1.93
Risk-free interest rate	1.95%	1.30%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)	$ 4.68	$ 5.26
Risk-free interest rate	2.14%	1.78%

STOCK-BASED COMPENSATION (Stock

STOCK-BASED COMPENSATION (Stock Option Award Activity) (Details) - $ / shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Number of Options Exercisable
Vested (in shares)			(125,880)
Common stock options
Number of Options outstanding
Outstanding at the beginning of the year (in shares)			801,690
Granted (in shares)	131,500	55,000	299,880	291,500
Exercised (in shares)			(27,818)
Forfeited (in shares)			(165,192)
Outstanding at the end of the reporting period (in shares)	908,560		908,560		801,690
Number of Options Exercisable
Exercisable at the beginning of the year (in shares)			419,174
Vested (in shares)			(329,733)
Forfeited (in shares)			(129,901)
Exercisable at the end of the reporting period (in shares)	591,188		591,188		419,174
Weighted Average Exercise Price Outstanding
Outstanding at the beginning of period (in dollars per share)			$ 5.25
Granted (in dollars per share)			4.44
Exercised (in dollars per share)			1.95
Forfeited (in dollars per share)			6.32
Outstanding at the end of the reporting period (in dollars per share)	$ 4.94		4.94		$ 5.25
Weighted Average Exercise Price Exercisable
Exercisable at the beginning of the reporting period (in dollars per share)			5.94
Vested exercisable (in dollars per share)			4.55
Forfeited (in dollars per share)			7.13
Exercisable at the end of the reporting period (in dollars per share)	5.30		5.30		5.94
Weighted Average Grant Date Fair Value Outstanding
Outstanding at the beginning of the reporting period (in dollars per share)			3.32
Granted (in dollars per share)			2.67
Exercised (in dollars per share)			1.16
Forfeited (in dollars per share)			4.15
Outstanding at the end of the reporting period (in dollars per share)	3.06		3.06		3.32
Weighted Average Grant Date Fair Value Exercisable
Exercisable at the beginning of the reporting period (in dollars per share)			3.86
Vested options exercisable (in dollars per share)			2.76
Exercised options exercisable (in dollars per share)			1.16
Forfeited options exercisable (in dollars per share)			4.69
Exercisable at the end of the reporting period (in dollars per share)	$ 3.32		$ 3.32		$ 3.86
Weighted Average Remaining Life In Years Outstanding
Outstanding Weighted Average Remaining Life (in years)			8 years 2 months 23 days		7 years 4 months 24 days
Granted (in years)			9 years 6 months 15 days
Weighted Average Remaining Life Exercisable
Exercisable, Weighted Average Remaining Life			7 years 11 months 23 days		6 years
Granted (in years)			8 years 6 months 26 days

STOCK-BASED COMPENSATION (Sto30

STOCK-BASED COMPENSATION (Stock Options Outstanding and Exercisable) (Details) - Common stock options - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Stock Options	908,560	801,690
Exercisable, Weighted Average Remaining Life	7 years 11 months 23 days	6 years
Exercisable Number of Stock Options	591,188	419,174
$1.93 – $2.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Stock Options	149,000
Exercisable, Weighted Average Remaining Life	8 years 4 months 6 days
Exercisable Number of Stock Options	55,884
$1.93 – $2.00 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range	$ 1.93
$1.93 – $2.00 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range	$ 2
$3.83 – $4.70
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Stock Options	369,880
Exercisable, Weighted Average Remaining Life	9 years 4 months 24 days
Exercisable Number of Stock Options	242,854
$3.83 – $4.70 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range	$ 3.83
$3.83 – $4.70 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range	$ 4.70
$5.06 – $6.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Stock Options	250,000
Exercisable, Weighted Average Remaining Life	6 years 10 months 13 days
Exercisable Number of Stock Options	192,509
$5.06 – $6.00 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range	$ 5.06
$5.06 – $6.00 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range	$ 6
$6.49 – $7.20
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Stock Options	50,000
Exercisable, Weighted Average Remaining Life	6 years 11 months 5 days
Exercisable Number of Stock Options	37,820
$6.49 – $7.20 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range	$ 6.49
$6.49 – $7.20 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range	$ 7.20
$7.54 – $7.55
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Stock Options	57,800
Exercisable, Weighted Average Remaining Life	7 years 2 months 16 days
Exercisable Number of Stock Options	38,202
$7.54 – $7.55 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range	$ 7.54
$7.54 – $7.55 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range	$ 7.55
$8.06 – $12.98
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Stock Options	31,880
Exercisable, Weighted Average Remaining Life	4 years 6 months 7 days
Exercisable Number of Stock Options	23,919
$8.06 – $12.98 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range	$ 8.06
$8.06 – $12.98 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range	$ 12.98

STOCK-BASED COMPENSATION (Restr

STOCK-BASED COMPENSATION (Restricted Stock Activity) (Details) - Restricted stock units - $ / shares	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016
Number of Restricted Share Units
Outstanding at beginning of year (in shares)		1,455,558
Granted (in shares)		529,907
Vested (in shares)	(79,831)	(532,031)	(222,043)
Canceled (in shares)		(51,741)
Outstanding at end of year (in shares)	1,401,693	1,401,693
Weighted- Average Grant-Date Fair Value
Outstanding at beginning of year (in dollars per share)		$ 3.64
Granted (in dollars per share)		4.48
Vested (in dollars per share)		4.20
Canceled (in dollars per share)		5.40
Outstanding at end of year (in dollars per share)	$ 4.53	$ 4.53

STOCK-BASED COMPENSATION (Equit

STOCK-BASED COMPENSATION (Equity Based Compensation Schedule) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Allocation of stock-based compensation expense
Stock compensation expense	$ 666	$ 552	$ 2,024	$ 1,350
Research and development expenses
Allocation of stock-based compensation expense
Stock compensation expense	324	177	900	515
Research and development expenses | Employees
Allocation of stock-based compensation expense
Stock compensation expense	304	172	839	497
Research and development expenses | Non-employees
Allocation of stock-based compensation expense
Stock compensation expense	20	5	61	18
General and administrative expenses
Allocation of stock-based compensation expense
Stock compensation expense	342	375	1,124	835
General and administrative expenses | Non-employees
Allocation of stock-based compensation expense
Stock compensation expense	28	94	126	130
General and administrative expenses | Employees and directors
Allocation of stock-based compensation expense
Stock compensation expense	$ 314	$ 281	$ 998	$ 705

RELATED PARTY TRANSACTION (Deta

RELATED PARTY TRANSACTION (Details) - Director - Engineering Design and Fabrication Advisory Services	3 Months Ended	9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2017USD ($)
Related Party Transaction [Line Items]
Related party advisory services agreement	$ 120,000	$ 120,000
Expenses from transactions with related party	$ 0	$ 26,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details)

Aug. 01, 2017USD ($)

Apr. 01, 2017USD ($)ft²

Dec. 16, 2016USD ($)ft²

Aug. 01, 2014USD ($)

May 30, 2015USD ($)

Apr. 30, 2014USD ($)

Nov. 30, 2013USD ($)

Oct. 31, 2013USD ($)

Sep. 30, 2017USD ($)

Sep. 30, 2016USD ($)

Sep. 30, 2017USD ($)

Sep. 30, 2016USD ($)

Mar. 17, 2015claims

Operating Leases

Legal expenses incurred

$ 750,000

Loss contingency accrual

$ 0

$ 0

0

$ 0

Loss in period

0

0

In re Resonant Inc. Securities Litigation, Case Number 15cv01970SJO (VBKx) | Pending Litigation

Operating Leases

Punitive class action lawsuits filed | claims

3

Corporate Headquarters

Operating Leases

Term of lease

38 months

Monthly rental payments

$ 13,987

$ 14,479

$ 8,286

$ 5,412

Increase in rental payments (as a percent)

3.00%

Period after which monthly rental increases

14 months

Monthly operating cost

$ 7,000

$ 3,154

$ 2,101

Renewal term of the lease

3 years

Tenant improvement allowance

$ 72,160

Additional tenant improvement allowance

$ 38,320

Area of real estate property | ft²

9,024

Satellite development office

Operating Leases

Term of lease

2 years

Monthly rental payments

$ 17,000

Renewal term of the lease

5 years

1 year

Area of real estate property | ft²

5,248

Rent expense

$ 5,000

$ 4,000

Facilities and equipment

Operating Leases

Rent expense

$ 127,000

$ 57,000

$ 339,000

$ 152,000

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($) $ / shares in Units, $ in Thousands	Oct. 02, 2017	Sep. 28, 2017	Feb. 28, 2017	Sep. 30, 2017	Sep. 30, 2016
Subsequent Event [Line Items]
Proceeds from the sale of common stock from private placement offering				$ 15,025	$ 5,177
Capital Units
Subsequent Event [Line Items]
New shares issued				2,715,000
Capital Units | Institutional and Individual Investors
Subsequent Event [Line Items]
Share price (in dollars per share)		$ 4.70
Capital Units | Placement Agent
Subsequent Event [Line Items]
Share price (in dollars per share)		$ 4.85
Capital Units | Private Placement, Offering One | Institutional and Individual Investors
Subsequent Event [Line Items]
Sold in private placement		1,745,581
Proceeds from the sale of common stock from private placement offering		$ 8,200
Proceeds from issuance of private placement, net of offering costs		$ 7,500
Capital Units | Private Placement, Offering Two | Institutional and Individual Investors | Subsequent Event
Subsequent Event [Line Items]
Sold in private placement	231,338
Proceeds from the sale of common stock from private placement offering	$ 1,100
Proceeds from issuance of private placement, net of offering costs	$ 1,000
Common stock warrants | Institutional and Individual Investors
Subsequent Event [Line Items]
Warrant exercise price		$ 4.85
Warrant term, period end after closing		3 years
Common stock warrants | Placement Agent
Subsequent Event [Line Items]
Warrant term, period start after closing		6 months	6 months
Warrant term, period end after closing		3 years
Common stock warrants | Placement Agent | Subsequent Event
Subsequent Event [Line Items]
Warrant term, period end after closing	3 years
Common stock warrants | Private Placement, Offering One | Placement Agent | Subsequent Event
Subsequent Event [Line Items]
Sold in private placement	87,279
Common stock warrants | Private Placement, Offering Two | Placement Agent | Subsequent Event
Subsequent Event [Line Items]
Sold in private placement	11,567
Private Placement Warrants | Capital Units | Private Placement Warrants - 2016 | Institutional and Individual Investors
Subsequent Event [Line Items]
New shares issued		1,976,919
Private Placement Warrants | Capital Units | Private Placement Warrants - 2016 | Placement Agent
Subsequent Event [Line Items]
New shares issued		98,846